Wednesday, 24 June 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 24 June 2026
News

Dept preps for more broad listings

Posted 24 June 2026 PM

The Federal Government is preparing for pharmas to follow the lead of BMS and MSD in seeking a broad listing for their cancer drugs, and has released guidelines for those considering a multi-indication listing for a PD-1 or PD-L1 inhibitor.

BMS landed a recommendation for a broad listing for its Opdivo and Yervoy combo from the PBAC last September, with the Committee saying the history making multi-indication listing got over the line due to a revised proposal with a risk-sharing agreement. The recommended broad listing hit the PBS in March.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (19)

Access & Reimbursement (2)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (6)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.